Abstract
Background Cancer therapeutic response patterns may be fundamentally influenced by embryonic germ layer origin. Emerging evidence suggests mesoderm-derived malignancies exhibit exceptional responsiveness to cellular immunotherapy, endoderm-derived epithelial cancers demonstrate marked sensitivity to protein signaling inhibitors, and ectoderm-derived tumors show heightened immunogenicity enabling breakthrough responses to checkpoint blockade and messenger RNA vaccine strategies.
Methods We conducted a systematic review following PRISMA 2020 guidelines. PubMed/MEDLINE, Embase, and Web of Science were searched from inception through 13 October 2025 using predefined PICOS criteria and a reproducible search strategy. A prespecified protocol (archived; no prior registry) guided screening, data extraction, and risk-of-bias assessment.
Eligibility We included patients with malignancies assignable to ectoderm, mesoderm, or endoderm lineages receiving cellular immunotherapies, protein-targeted agents/antibody-drug conjugates, or nucleic acid/immunomodulatory therapies. Eligible comparators included active controls, standard care, placebo, or single-arm designs where appropriate. Study designs comprised randomized controlled trials, non-randomized comparative studies, and pivotal single-arm trials in refractory settings. We excluded preclinical studies, case reports/series with fewer than ten patients, studies without extractable endpoints, duplicate/superseded publications, and cancers with unassignable lineage.
Outcomes and Analysis Primary outcomes were objective response rate, progression-free survival, and overall survival. Secondary outcomes included complete response, duration of response, event-free/recurrence-free survival, and safety. Effect measures were hazard ratios for time-to-event data and risk/odds ratios for binary outcomes. Random-effects meta-analysis was planned for clinically and statistically homogeneous subsets; otherwise, we performed SWiM-compliant narrative synthesis with megatrend analysis given extreme clinical heterogeneity. Evidence synthesis incorporated National Comprehensive Cancer Network Clinical Practice Guidelines, American Society of Clinical Oncology publications, American Cancer Society statistics, and landmark phase III/IV clinical trials.
Verification Clinical outcome data underwent triple-checking using independent search strategies. Large language model tools assisted with abstract screening prioritization only; all eligibility assessment, data extraction, risk-of-bias evaluation, and synthesis were performed exclusively by human reviewers.
Findings Three major megatrends emerged. First, mesoderm-derived hematologic malignancies achieved complete response rates of 82-97% with chimeric antigen receptor T-cell therapies across multiple pivotal trials. Second, endoderm-derived adenocarcinomas demonstrated consistent vulnerability to targeted therapies, with median overall survival of 19-47 months when treated with matched protein pathway inhibitors. Third, ectoderm-derived melanoma exhibited sustained immune control, with checkpoint blockade achieving 43% ten-year overall survival in advanced disease and personalized messenger RNA neoantigen vaccines providing 49% risk reduction for recurrence in the adjuvant setting.
Interpretation Embryonic germ layer origin provides valuable exploratory context for understanding cancer therapeutic response patterns. This developmental framework complements molecular biomarker-driven precision oncology and may inform treatment selection, clinical trial design, and drug development prioritization.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The approach and structure of the review was modified to encompass more information and adapt current insights from guidelines and updated research into the logical frameworks. The discussion now posits from a narrative viewpoint where the topography of oncology research is presented within the categorization of a developmental biology lens.
Data Availability
All data produced in the present work are contained in the manuscript
